Previous 10 | Next 10 |
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Offi...
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and Sara...
Nykode Therapeutics, formerly Vaccibody (OTCPK:VACBF), and Regeneron Pharmaceuticals (NASDAQ:REGN) have entered into a license and development agreement for three cancer and two infectious disease programs. Nykode is responsible for vaccine generation and characterization, and product supply ...
Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development under the collaboration Decibel to receive $10 million extension payment from Reg...
H.C. Wainwright has initiated shares of Decibel Therapeutics with a buy rating (DBTX +0.3%) due to the company's focus on therapies for hearing and balance diseases, many of which have significant unmet medical needs. The firm has a price target of $23 (216% upside). Analyst Emanuela Branchet...
Decibel Therapeutics (NASDAQ:DBTX): Q3 GAAP EPS of -$0.66 misses by $0.23. As of September 30, 2021, we had cash, cash equivalents and available-for-sale securities of $172.4 million. Press Release For further details see: Decibel Therapeutics EPS misses by $0.23
- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of DB-020 Phase 1b trial for ...
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays ...
Gainers: Digital World Acquisition DWAC +14%. Athira Pharma ATHA +6%. Mattel MAT +5%. Decibel Therapeutics (NASDAQ:DBTX) +4%. The Vita Coco (NASDAQ:COCO) +3%. Losers: Cambium Networks CMBM -14%. DMC Global BOOM -11%. Intel INTC -7%. Xiaobai Maimai (NASDAQ:HX...
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Offi...
News, Short Squeeze, Breakout and More Instantly...
Decibel Therapeutics Inc. Company Name:
DBTX Stock Symbol:
NASDAQ Market:
Decibel Therapeutics Inc. Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Decibel Therapeutics Inc. (DBTX) is expected to report $-0.61 for Q3 2023
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc. (NASDAQ:...